[96a5a0]: / output / allTrials / identified / NCT00090701_identified.json

Download this file

738 lines (738 with data), 34.4 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
{
"info": {
"nct_id": "NCT00090701",
"official_title": "A Phase 2, Open-Label, Multicenter Study Of The GARFT Inhibitor AG2037 In Patients With MetastatIC Non Small Cell Lung Cancer Who Failed Two Or Three Prior Treatments",
"inclusion_criteria": "* presence of measurable, metastatic non-small cell lung cancer (histologically or cytologically confirmed at the time of original diagnosis)\n* treatment failure (recurrence, disease progression, or intolerable toxicity) of 2 or 3 prior systemic treatments. (Note: no more than 3 prior systemic regimens for non-small cell lung cancer including adjuvant chemotherapy)\n* capable of understanding the nature of the trial and willing to give written informed consent\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2\n* hemoglobin level of >=9 g/dL, absolute granulocyte count of >=1.5 &#215; 109/L, and platelet count of >=100 &#215; 109/L\n* adequate renal function, as documented by a serum creatinine level of <=1.5 times the institutional upper limit of normal (ULN) and a measured or calculated creatinine clearance of >=60 mL/min\n* adequate liver function, as demonstrated by a total bilirubin level of <=1.5 times ULN; levels of serum glutamate oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) <=2 times ULN. If the patient has liver involvement then AST and ALT should be <=5 times ULN\n* for men with partners of child-bearing potential and all women of childbearing potential, willingness to use adequate contraception or practice abstinence during the course of the study at least 18 years of age\n* life expectancy estimated at greater than 12 weeks\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* history of blood transfusion within the last 14 days\n* need of concurrent administration of allopurinol\n* history of radiotherapy or chemotherapy within 4 weeks (nitrosourea or mitomycin C within 6 weeks) of the anticipated first day of dosing (patient must be fully recovered from the acute effects of any prior chemotherapy or radiotherapy)\n* any psychological or sociological condition, addictive disorder, or family problems that might preclude compliance with the protocol\n* any unstable or severe intercurrent medical condition that in the opinion of the investigator might interfere with achievement of study objectives\n* receipt of an investigational agent within 28 days before the anticipated first day of dosing (patient must have recovered from all acute effects of previously administered investigational agents)\n* pregnant or breast-feeding\n* previous treatment with GARFT inhibitors\n* history of radiation therapy to more than 40% of the marrow space\n* history of a malignancy (other than non-small cell lung cancer) except those treated with curative intent for skin cancer (other than melanoma) or in situ breast or cervical cancer or those treated with curative intent for any other cancer with no evidence of disease for 5 years\n* active brain metastases (requiring treatment or progressing)",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* presence of measurable, metastatic non-small cell lung cancer (histologically or cytologically confirmed at the time of original diagnosis)",
"criterions": [
{
"exact_snippets": "presence of measurable, metastatic non-small cell lung cancer",
"criterion": "non-small cell lung cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
},
{
"requirement_type": "measurable",
"expected_value": true
},
{
"requirement_type": "metastatic",
"expected_value": true
}
]
},
{
"exact_snippets": "histologically or cytologically confirmed at the time of original diagnosis",
"criterion": "non-small cell lung cancer confirmation",
"requirements": [
{
"requirement_type": "method",
"expected_value": [
"histologically",
"cytologically"
]
},
{
"requirement_type": "timing",
"expected_value": "at the time of original diagnosis"
}
]
}
]
},
{
"line": "* treatment failure (recurrence, disease progression, or intolerable toxicity) of 2 or 3 prior systemic treatments. (Note: no more than 3 prior systemic regimens for non-small cell lung cancer including adjuvant chemotherapy)",
"criterions": [
{
"exact_snippets": "treatment failure (recurrence, disease progression, or intolerable toxicity)",
"criterion": "treatment failure",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "2 or 3 prior systemic treatments",
"criterion": "prior systemic treatments",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 2,
"unit": "N/A"
},
{
"operator": "<=",
"value": 3,
"unit": "N/A"
}
]
}
}
]
},
{
"exact_snippets": "no more than 3 prior systemic regimens for non-small cell lung cancer",
"criterion": "prior systemic regimens for non-small cell lung cancer",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": "<=",
"value": 3,
"unit": "N/A"
}
}
]
}
]
},
{
"line": "* capable of understanding the nature of the trial and willing to give written informed consent",
"criterions": [
{
"exact_snippets": "capable of understanding the nature of the trial",
"criterion": "understanding of trial",
"requirements": [
{
"requirement_type": "capability",
"expected_value": true
}
]
},
{
"exact_snippets": "willing to give written informed consent",
"criterion": "informed consent",
"requirements": [
{
"requirement_type": "willingness",
"expected_value": true
}
]
}
]
},
{
"line": "* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2",
"criterion": "ECOG Performance Status",
"requirements": [
{
"requirement_type": "status",
"expected_value": [
"0",
"1",
"2"
]
}
]
}
]
},
{
"line": "* adequate renal function, as documented by a serum creatinine level of <=1.5 times the institutional upper limit of normal (ULN) and a measured or calculated creatinine clearance of >=60 mL/min",
"criterions": [
{
"exact_snippets": "adequate renal function, as documented by a serum creatinine level of <=1.5 times the institutional upper limit of normal (ULN)",
"criterion": "serum creatinine level",
"requirements": [
{
"requirement_type": "comparison",
"expected_value": {
"operator": "<=",
"value": 1.5,
"unit": "times the institutional upper limit of normal (ULN)"
}
}
]
},
{
"exact_snippets": "adequate renal function, ... a measured or calculated creatinine clearance of >=60 mL/min",
"criterion": "creatinine clearance",
"requirements": [
{
"requirement_type": "comparison",
"expected_value": {
"operator": ">=",
"value": 60,
"unit": "mL/min"
}
}
]
}
]
},
{
"line": "* adequate liver function, as demonstrated by a total bilirubin level of <=1.5 times ULN; levels of serum glutamate oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) <=2 times ULN. If the patient has liver involvement then AST and ALT should be <=5 times ULN",
"criterions": [
{
"exact_snippets": "adequate liver function, as demonstrated by a total bilirubin level of <=1.5 times ULN",
"criterion": "total bilirubin level",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": {
"operator": "<=",
"value": 1.5,
"unit": "times ULN"
}
}
]
},
{
"exact_snippets": "levels of serum glutamate oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) ... <=2 times ULN",
"criterion": "serum glutamate oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST])",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "times ULN"
}
}
]
},
{
"exact_snippets": "serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) <=2 times ULN",
"criterion": "serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT])",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "times ULN"
}
}
]
},
{
"exact_snippets": "If the patient has liver involvement then AST and ALT should be <=5 times ULN",
"criterion": "AST and ALT levels with liver involvement",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 5,
"unit": "times ULN"
}
}
]
}
]
},
{
"line": "* for men with partners of child-bearing potential and all women of childbearing potential, willingness to use adequate contraception or practice abstinence during the course of the study at least 18 years of age",
"criterions": [
{
"exact_snippets": "men with partners of child-bearing potential and all women of childbearing potential, willingness to use adequate contraception or practice abstinence during the course of the study",
"criterion": "contraception or abstinence",
"requirements": [
{
"requirement_type": "willingness",
"expected_value": true
}
]
},
{
"exact_snippets": "at least 18 years of age",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum age",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
]
}
]
},
{
"line": "* life expectancy estimated at greater than 12 weeks",
"criterions": [
{
"exact_snippets": "life expectancy estimated at greater than 12 weeks",
"criterion": "life expectancy",
"requirements": [
{
"requirement_type": "estimate",
"expected_value": {
"operator": ">",
"value": 12,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* history of blood transfusion within the last 14 days",
"criterions": [
{
"exact_snippets": "history of blood transfusion within the last 14 days",
"criterion": "blood transfusion",
"requirements": [
{
"requirement_type": "history",
"expected_value": {
"operator": "<=",
"value": 14,
"unit": "days"
}
}
]
}
]
},
{
"line": "* need of concurrent administration of allopurinol",
"criterions": [
{
"exact_snippets": "need of concurrent administration of allopurinol",
"criterion": "concurrent administration of allopurinol",
"requirements": [
{
"requirement_type": "need",
"expected_value": true
}
]
}
]
},
{
"line": "* history of radiotherapy or chemotherapy within 4 weeks (nitrosourea or mitomycin C within 6 weeks) of the anticipated first day of dosing (patient must be fully recovered from the acute effects of any prior chemotherapy or radiotherapy)",
"criterions": [
{
"exact_snippets": "history of radiotherapy or chemotherapy within 4 weeks",
"criterion": "history of radiotherapy or chemotherapy",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 4,
"unit": "weeks"
}
]
}
}
]
},
{
"exact_snippets": "nitrosourea or mitomycin C within 6 weeks",
"criterion": "history of nitrosourea or mitomycin C",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 6,
"unit": "weeks"
}
]
}
}
]
},
{
"exact_snippets": "patient must be fully recovered from the acute effects of any prior chemotherapy or radiotherapy",
"criterion": "recovery from acute effects of prior chemotherapy or radiotherapy",
"requirements": [
{
"requirement_type": "recovery status",
"expected_value": "fully recovered"
}
]
}
]
},
{
"line": "* any psychological or sociological condition, addictive disorder, or family problems that might preclude compliance with the protocol",
"criterions": [
{
"exact_snippets": "any psychological ... condition",
"criterion": "psychological condition",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "any ... sociological condition",
"criterion": "sociological condition",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "any ... addictive disorder",
"criterion": "addictive disorder",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "any ... family problems",
"criterion": "family problems",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* any unstable or severe intercurrent medical condition that in the opinion of the investigator might interfere with achievement of study objectives",
"criterions": [
{
"exact_snippets": "any unstable or severe intercurrent medical condition",
"criterion": "intercurrent medical condition",
"requirements": [
{
"requirement_type": "severity",
"expected_value": [
"unstable",
"severe"
]
}
]
},
{
"exact_snippets": "in the opinion of the investigator might interfere with achievement of study objectives",
"criterion": "interference with study objectives",
"requirements": [
{
"requirement_type": "opinion",
"expected_value": "investigator"
}
]
}
]
},
{
"line": "* receipt of an investigational agent within 28 days before the anticipated first day of dosing (patient must have recovered from all acute effects of previously administered investigational agents)",
"criterions": [
{
"exact_snippets": "receipt of an investigational agent within 28 days before the anticipated first day of dosing",
"criterion": "receipt of investigational agent",
"requirements": [
{
"requirement_type": "time since last dose",
"expected_value": {
"operator": "<",
"value": 28,
"unit": "days"
}
}
]
},
{
"exact_snippets": "patient must have recovered from all acute effects of previously administered investigational agents",
"criterion": "recovery from acute effects of investigational agents",
"requirements": [
{
"requirement_type": "recovery",
"expected_value": true
}
]
}
]
},
{
"line": "* pregnant or breast-feeding",
"criterions": [
{
"exact_snippets": "pregnant",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "breast-feeding",
"criterion": "breastfeeding",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* previous treatment with GARFT inhibitors",
"criterions": [
{
"exact_snippets": "previous treatment with GARFT inhibitors",
"criterion": "previous treatment with GARFT inhibitors",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* history of radiation therapy to more than 40% of the marrow space",
"criterions": [
{
"exact_snippets": "history of radiation therapy",
"criterion": "radiation therapy history",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "more than 40% of the marrow space",
"criterion": "radiation therapy coverage",
"requirements": [
{
"requirement_type": "coverage",
"expected_value": {
"operator": ">",
"value": 40,
"unit": "%"
}
}
]
}
]
},
{
"line": "* history of a malignancy (other than non-small cell lung cancer) except those treated with curative intent for skin cancer (other than melanoma) or in situ breast or cervical cancer or those treated with curative intent for any other cancer with no evidence of disease for 5 years",
"criterions": [
{
"exact_snippets": "history of a malignancy (other than non-small cell lung cancer)",
"criterion": "history of malignancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "except those treated with curative intent for skin cancer (other than melanoma)",
"criterion": "treatment intent for skin cancer",
"requirements": [
{
"requirement_type": "intent",
"expected_value": "curative"
}
]
},
{
"exact_snippets": "except those treated with curative intent for skin cancer (other than melanoma)",
"criterion": "type of skin cancer",
"requirements": [
{
"requirement_type": "type",
"expected_value": "non-melanoma"
}
]
},
{
"exact_snippets": "in situ breast or cervical cancer",
"criterion": "type of cancer",
"requirements": [
{
"requirement_type": "type",
"expected_value": [
"in situ breast cancer",
"in situ cervical cancer"
]
}
]
},
{
"exact_snippets": "those treated with curative intent for any other cancer with no evidence of disease for 5 years",
"criterion": "treatment intent for other cancers",
"requirements": [
{
"requirement_type": "intent",
"expected_value": "curative"
}
]
},
{
"exact_snippets": "those treated with curative intent for any other cancer with no evidence of disease for 5 years",
"criterion": "evidence of disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "those treated with curative intent for any other cancer with no evidence of disease for 5 years",
"criterion": "disease-free duration",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 5,
"unit": "years"
}
}
]
}
]
},
{
"line": "* active brain metastases (requiring treatment or progressing)",
"criterions": [
{
"exact_snippets": "active brain metastases (requiring treatment or progressing)",
"criterion": "brain metastases",
"requirements": [
{
"requirement_type": "activity",
"expected_value": "active"
},
{
"requirement_type": "treatment requirement",
"expected_value": true
},
{
"requirement_type": "progression",
"expected_value": true
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [
{
"line": "* hemoglobin level of >=9 g/dL, absolute granulocyte count of >=1.5 &#215; 109/L, and platelet count of >=100 &#215; 109/L",
"criterions": [
{
"exact_snippets": "hemoglobin level of >=9 g/dL",
"criterion": "hemoglobin level",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 9,
"unit": "g/dL"
}
}
]
},
{
"exact_snippets": "absolute granulocyte count of >=1.5 × 109/L",
"criterion": "absolute granulocyte count",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1.5,
"unit": "× 109/L"
}
}
]
},
{
"exact_snippets": "platelet count of >=100 × 109/L",
"criterion": "platelet count",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 100,
"unit": "× 109/L"
}
}
]
}
]
}
],
"failed_exclusion": [],
"failed_miscellaneous": []
}